TELO

Handel nachbörslich: 5.70 -0.30 -5.00%

Telomir Pharmaceuticals Inc (TELO)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Telomir Pharmaceuticals Inc

(813) 864-2562

900 WEST PLATT STREET, SUITE 200, TAMPA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

TELO's Discussions on Twitter

Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten

Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)

Telomir Pharmaceuticals Inc (TELO)

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Increase in Short Interest - MarketBeat

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 2.2% - Defense World

Telomir Pharmaceuticals (NASDAQ:TELO) Trading 2.2% Higher - MarketBeat

Three biotechs raise $700M in rare burst of IPO activity - BioPharma Dive

What Is Going On With AST SpaceMobile Stock? - Barchart

Experience The Future Of Smart Living With Hisense At IFA 2024 - Barchart

Boeing's troubled space capsule ends mission with a landing in the New Mexico desert, leaving two astronauts in orbit - Barchart

Stakeholder In Trump's Truth Social Parent Company Wins Court Ruling Over Share Transfer - Barchart

Is RTX Corporation Stock Outperforming The S&P 500? - Barchart

US Hiring Rebounds Slightly And Unemployment Rate Dips In Sign Of Still-Slowing Job Market - Barchart

Telegram CEO Defends Himself Against French Charges In First Public Comments - Barchart

New Mexico attorney general sues company behind Snapchat alleging child sexual extortion on the site - Barchart

IGM FINANCIAL INC. ANNOUNCES AUGUST 2024 ASSETS UNDER MANAGEMENT & ADVISEMENT AND NET FLOWS - Barchart

Media AdvisoryPrime Minister's Itinerary For Friday, September 6, 2024 - Barchart

ALIMENTATION COUCHE-TARD INC. ANNOUNCES ELECTION OF DIRECTORS - Barchart

With Musk's X Banned In Brazil, Its Users Carve Out New Digital Homes - Barchart

Telomir Pharmaceuticals’ Age Reversal Drug Shows Promise in Canine Study - Vancity Buzz

Obesity Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novo Nordisk, Boehringer Ingelheim, Pfizer, BioAge Labs, Aphaia Pharma, Neothetics, NovMetaPharma, Carmot - Barchart

Applications For US Jobless Benefits Fall To 2-Month Low As Layoffs Remain At Healthy Levels - Barchart

WCAS Completes Acquisition Of EquiLend - Barchart

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs | FinancialContent Business Page - Financial Content

Soft Tissue Sarcoma Market is expected to grow at a significant CAGR, DelveInsight | Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm - Barchart

FuelCell Energy: Fiscal Q3 Earnings Snapshot - Barchart

Telomir names Dr. Itzchak Angel as Chief Scientific Advisor - Investing.com

Telomir names Dr. Itzchak Angel as Chief Scientific Advisor - Investing.com India

Unusual Activity In Block Inc. OptionsHighlights SQ Stock's Value - Barchart

Telomir names Dr. Itzchak Angel as Chief Scientific Advisor By Investing.com - Investing.com Canada

Protecting Homeowners From Unnecessary Financial Stress - Barchart

US Job Openings Fall As Demand For Workers Cools - Barchart

Telomir Pharmaceuticals recruits ex-Synthelabo executive By Investing.com - Investing.com Australia

Amyotrophic Lateral Sclerosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Amylyx Pharma, Ionis Pharma, Annexon, Inc., UniQure Biopharma, Sangamo Therapeutics - Barchart

Markey and Warren condemn Steward's CEO for refusing to comply with a Senate subpoena - Barchart

Telomir names Dr. Itzchak Angel as Chief Scientific Advisor By Investing.com - Investing.com UK

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications - Milton Daily Standard

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications - AccessWire

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications - StockTitan

Telomir Pharmaceuticals recruits ex-Synthelabo executive - Investing.com

Eaton Corporation Stock: Is ETN Outperforming The Industrials Sector? - Barchart

Is Union Pacific Corporation Stock Outperforming The Dow? - Barchart

The growth track for Telomir Pharmaceuticals Inc (TELO) has changed recently - SETE News

Quarterly Metrics: Quick and Current Ratios for Telomir Pharmaceuticals Inc (TELO) - The Dwinnex

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart

Mira Pharmaceuticals (NASDAQ:MIRA) Stock Quotes, Forecast and News Summary - Benzinga

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Up 3.2% - MarketBeat

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Up 3.2% - Defense World

Telomir-1 shows promise in aging dogs, eyes human trials - Investing.com

TELO Stock: Exploring Telomir Pharmaceuticals Inc’s Growth - The InvestChronicle

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs - Milton Daily Standard

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs - Brazosport Facts

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs - AccessWire

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs - StockTitan

Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie TELO